Lisa Cook sues Trump over firing attempt, emergency hearing set
Investing.com -- A U.S. federal judge has upheld a decision by the U.S. Food and Drug Administration (FDA) to remove Eli Lilly (NYSE:LLY)’s top-selling weight loss and diabetes drugs, Zepbound and Mounjaro, from a list of medicines in short supply. The ruling could affect patients who were hoping to regain access to less expensive versions of these popular treatments.
The FDA’s decision has also impacted compounding pharmacies, which had been permitted to produce hundreds of thousands of doses of obesity drug copies while a shortage was declared by the FDA.
U.S. District Judge Mark Pittman in Texas issued the sealed order on Wednesday in response to a lawsuit filed in October by a compounding industry group against the FDA’s directive. In March, the judge denied a request from compounding pharmacies to continue producing copies of Zepbound and Mounjaro while the lawsuit was ongoing.
As of March 19, all compounding pharmacies, including larger outsourcing facilities, were instructed to stop producing copies of the drugs. A reversed ruling by the judge could have allowed these pharmacies to resume production.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.